<?xml version='1.0' encoding='utf-8'?>
<document id="16595573"><sentence text="Hepatic veno-occlusive disease associated with immunosuppressive cyclophosphamide dosing and roxithromycin."><entity charOffset="65-81" id="DDI-PubMed.16595573.s1.e0" text="cyclophosphamide" /><entity charOffset="93-106" id="DDI-PubMed.16595573.s1.e1" text="roxithromycin" /><pair ddi="false" e1="DDI-PubMed.16595573.s1.e0" e2="DDI-PubMed.16595573.s1.e0" /><pair ddi="false" e1="DDI-PubMed.16595573.s1.e0" e2="DDI-PubMed.16595573.s1.e1" /></sentence><sentence text="To report on a patient developing hepatic veno-occlusive disease while being treated with immunosuppressive doses of cyclophosphamide (&lt; or =2 mg/kg)"><entity charOffset="117-133" id="DDI-PubMed.16595573.s2.e0" text="cyclophosphamide" /></sentence><sentence text="" /><sentence text="A 66-year-old woman with autoimmune hemolytic anemia developed hepatic veno-occlusive disease while being treated with immunosuppressive cyclophosphamide 100 mg/day in combination with roxithromycin (total dose 600 mg/day)"><entity charOffset="137-153" id="DDI-PubMed.16595573.s4.e0" text="cyclophosphamide" /><entity charOffset="185-198" id="DDI-PubMed.16595573.s4.e1" text="roxithromycin" /><pair ddi="false" e1="DDI-PubMed.16595573.s4.e0" e2="DDI-PubMed.16595573.s4.e0" /><pair ddi="false" e1="DDI-PubMed.16595573.s4.e0" e2="DDI-PubMed.16595573.s4.e1" /></sentence><sentence text=" After all drugs were stopped, the patient recovered within 2 weeks" /><sentence text=" The Naranjo probability scale indicated a probable relationship between veno-occlusive disease and treatment with cyclophosphamide in this patient"><entity charOffset="115-131" id="DDI-PubMed.16595573.s6.e0" text="cyclophosphamide" /></sentence><sentence text="" /><sentence text="Since roxithromycin inhibits CYP3A4, which is involved with cyclophosphamide metabolism, a drug-drug interaction could have been responsible"><entity charOffset="6-19" id="DDI-PubMed.16595573.s8.e0" text="roxithromycin" /><entity charOffset="60-76" id="DDI-PubMed.16595573.s8.e1" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.16595573.s8.e0" e2="DDI-PubMed.16595573.s8.e0" /><pair ddi="false" e1="DDI-PubMed.16595573.s8.e0" e2="DDI-PubMed.16595573.s8.e1" /></sentence><sentence text=" In addition, roxithromycin is an inhibitor of the drug transporter P-glycoprotein, possibly leading to accumulation of cyclophosphamide in endothelial cells"><entity charOffset="14-27" id="DDI-PubMed.16595573.s9.e0" text="roxithromycin" /><entity charOffset="120-136" id="DDI-PubMed.16595573.s9.e1" text="cyclophosphamide" /><pair ddi="false" e1="DDI-PubMed.16595573.s9.e0" e2="DDI-PubMed.16595573.s9.e0" /><pair ddi="false" e1="DDI-PubMed.16595573.s9.e0" e2="DDI-PubMed.16595573.s9.e1" /></sentence><sentence text=" Alternatively, since cyclophosphamide has been reported to induce apoptosis, roxithromycin could have rendered endothelial cells more vulnerable for apoptosis"><entity charOffset="22-38" id="DDI-PubMed.16595573.s10.e0" text="cyclophosphamide" /><entity charOffset="78-91" id="DDI-PubMed.16595573.s10.e1" text="roxithromycin" /><pair ddi="false" e1="DDI-PubMed.16595573.s10.e0" e2="DDI-PubMed.16595573.s10.e0" /><pair ddi="false" e1="DDI-PubMed.16595573.s10.e0" e2="DDI-PubMed.16595573.s10.e1" /></sentence><sentence text="" /><sentence text="In specific patients, cyclophosphamide can be associated with hepatic veno-occlusive disease at immunosuppressive doses"><entity charOffset="22-38" id="DDI-PubMed.16595573.s12.e0" text="cyclophosphamide" /></sentence><sentence text="" /></document>